• AstraZeneca advanced oral GLP-1 drug elecoglipron into Phase III following positive mid-stage trials in obesity, overweight, type 2 diabetes.
• Results were presented at the 2026 American Diabetes Association meeting, published in The Lancet.
• Studies showed meaningful weight loss in obesity, improved blood sugar control in type 2 diabetes, supporting broader cardiometabolic positioning.
• Safety profile aligned with GLP-1 drugs, dominated by gastrointestinal side effects, with no liver safety signal flagged.
• Phase III plan includes EMBOLD obesity trials, ELUMINATE diabetes trials, cardiovascular and kidney outcome studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.